Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients

Summary

The goal of this clinical trial is to test dapagliflizone in Fabry patients. The main questions it aims to answer are: * Has 10 mg/d of dapagliflozin a positive effect on kidney functions of Fabry patients. * Has 10 mg/d of dapagliflozin a positive effect on heart functions in Fabry patients. Participants will be asked to * Sign an informed consent * Give a blood and urine samples * Be subjected to Echocardiography investigation * Take 10 mg/day Dapagliflizone Researchers will compare treatment to placebo groups to see if kidneys and heart functions will be improved in the treatment group better more than the placebo group.

Timeline

Start

2023-08

Primary completion

2024-08

Completion

2024-08

Drugs

Indications